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Abstract
Patients with ischaemic heart disease or chronic heart failure show altered levels of obestatin, suggesting a role for this peptide in human heart
function. We have previously demonstrated that GH secretagogues and the ghrelin gene-derived peptides, including obestatin, exert cardiovas-
cular effects by modulating cardiac inotropism and vascular tone, and reducing cell death and contractile dysfunction in hearts subjected to
ischaemia/reperfusion (I/R), through the Akt/nitric oxide (NO) pathway. However, the mechanisms underlying the cardiac actions of obestatin
remain largely unknown. Thus, we suggested that obestatin-induced activation of PI3K/Akt/NO and PKG signalling is implicated in protection of
the myocardium when challenged by adrenergic, endothelinergic or I/R stress. We show that obestatin exerts an inhibitory tone on the perfor-
mance of rat papillary muscle in both basal conditions and under b-adrenergic overstimulation, through endothelial-dependent NO/cGMP/PKG
signalling. This pathway was also involved in the vasodilator effect of the peptide, used both alone and under stress induced by endothelin-1.
Moreover, when infused during early reperfusion, obestatin reduced infarct size in isolated I/R rat hearts, through an NO/PKG pathway, com-
prising ROS/PKC signalling, and converging on mitochondrial ATP-sensitive potassium [mitoK(ATP)] channels. Overall, our results suggest that
obestatin regulates cardiovascular function in stress conditions and induces cardioprotection by mechanisms dependent on activation of an
NO/soluble guanylate cyclase (sGC)/PKG pathway. In fact, obestatin counteracts exaggerated b-adrenergic and endothelin-1 activity, relevant
factors in heart failure, suggesting multiple positive effects of the peptide, including the lowering of cardiac afterload, thus representing a poten-
tial candidate in pharmacological post-conditioning.
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Introduction
Several studies have suggested an important role for the growth hor-
mone (GH)-releasing peptides, such as ghrelin and GH secretagogues
(GHS), or the ghrelin gene-derived product obestatin, as homeostatic
regulators of the cardiovascular system [1–4]. These peptides have
been shown to modulate cardiac inotropism [5–8] and vascular tone
[9–14], and to reduce cell death and contractile dysfunction in hearts
subjected to ischaemia/reperfusion (I/R) [15–17].
Obestatin may play a role in cardiac function in humans, in both
physiological and pathological conditions [18]. Indeed, obestatin
levels were slightly increased in saliva of overweight patients with
ischaemic heart disease [19], while they were reduced in serum of
patients with type 2 diabetes mellitus [20] and obesity [21], two
pathological conditions associated with cardiovascular diseases. The
levels of both ghrelin and obestatin were found increased in patients
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with chronic heart failure and cachexia [22] as well as in sponta-
neously hypertensive rats (SHR) [23]. Yet, recent studies showed that
obestatin may exert beneficial cardiovascular effects in humans, by
producing vascular relaxation through activation of endothelium-
dependent nitric oxide (NO) signalling [24]. The link between obesta-
tin and NO has been confirmed in obese subject, where obestatin
induced vascular relaxation via specific activation of endothelium-
dependent NO signalling [25].
We have previously shown that pre-treatment of isolated rat
hearts with obestatin reduced infarct size and contractile dysfunction
induced by I/R. In addition, obestatin exerted a similar precondition-
ing-like effect in rat H9c2 cells and isolated ventricular myocytes, dis-
playing an antiapoptotic effect when these cells were subjected to I/R.
In these two preconditioning models, the protective effect of obestatin
was due to activation of protein kinase C (PKC), phosphoinositide 3-
kinase (PI3K) or extracellular signal-regulated kinase (ERK)1/2 path-
ways [15]. Despite the above observations, to date, the physiological
role of obestatin in stress conditions is still largely unknown and its
cardiovascular effects need to be studied further.
As PI3K may lead to NOS activation via Akt phosphorylation, it
can be argued that NO plays a role also in the regulation of car-
diac function and in cardioprotection by obestatin. Our hypothesis
is that the activation of PI3K/Akt/NO and protein kinase G (PKG)
pathway by obestatin is involved in protecting the heart when
challenged by either adrenergic, endothelinergic or I/R stress. To
test this hypothesis, obestatin-induced modulation of adrenergic or
endothelinergic response in non-ischaemic conditions was studied
in rat papillary muscle and whole heart, respectively. Moreover,
the protective effect of obestatin against I/R injury was assessed
in post-ischaemic Langendorff rat heart. As in post-conditioning
the PI3K/Akt/NO and PKG pathways converge on mitochondrial K
(ATP) [mito K(ATP)] channels [26], we also verified the involve-
ment of mitoK(ATP) in this context.
Materials and methods
Reagents
Rat obestatin was purchased from Tocris (Bristol, UK). The chemicals
were purchased from Sigma-Aldrich (St. Louis, MO, USA). The reagents
to assess myocardial infarction were provided by Merck (Darmstadt,
Germany). Antibodies for Phospho-eNOS (Catalog #9571), eNOS (Cata-
log #9572) and PKG-1 (Catalog #13511s) were from Cell Signaling
Technology (Euroclone, Milan, Italy); antibody for actin was from Santa
Cruz Biotechnology (DBA, Milan, Italy), (Catalog #sc-376421).
Animals
Male Wistar rats (n = 80; body weight 450–550 g, age 3–4 months)
received human care in compliance with the Italian law. All procedures
were performed according to institutional guidelines in compliance with
the Italian law (DL-116, Jan. 27, 1992 and D.L. N.26, 04/03/2014) and
International law and policies (new directive 2010/63/EU). The protocol
was approved by the Ethical Committee of the University of Turin and
by the Italian Ministry of Health.
Isolated papillary muscle
Papillary muscles were dissected free from the left ventricle under a
stereomicroscope, superfused with oxygenated Tyrode solution (compo-
sition, in mM: 154 NaCl, four KCl, two CaCl2, one MgCl2, 5.5 D-glucose
and five HEPES; pH adjusted to 7.35 with NaOH) at 37°C, and driven at
constant frequency (120 beats/min.) with a pair of electrodes connected
to a stimulator (302 T Anapulse; W. P. Instruments, New Haven, CT,
USA) via a stimulus isolator (model 305-R; W. P. Instruments) operating
in constant-current mode. Isometric twitches were evaluated by a trans-
ducer (model 60-2997; Harvard Instruments) and continuously acquired
and recorded by a PowerMac computer using Labview software (National
Instruments, Italy) [27]. Before each experiment, papillary muscles were
equilibrated in oxygenated (100% O2) Tyrode solution for 30 min. In pre-
liminary experiments, we tested the effects of different concentrations of
obestatin (25, 50 and 100 nM) in basal experimental condition. The mini-
mal concentration of obestatin (Tocris) giving a significant inotropic effect
(50 nM, see Results) was chosen to study its antiadrenergic effect. To
this purpose, the positive inotropic effect induced by b-adrenergic stimu-
lation (isoproterenol, ISO, 100 nM) was compared to that exerted by ISO
in the presence of 50 nM obestatin on the same preparation (n = 5).
Each treatment lasted 10 min., then the perfusion was switched to Tyrode
solution alone to study the reversibility of the effect. NG-nitro-L-arginine
methyl ester (L-NNA, 1 mM) was used to block NO synthesis, Wortman-
nin (WN, 100 nM) to block PI3K activity and 1H-[1,2,4] oxadiazole-[4,4-
a] quinoxalin-1-one (ODQ, 10 lM) to block guanylate cyclase (GC)
activity (in each case, n = 5). Five experiments were performed in the
presence of (D-Lys3)-GHRP-6 (1 lM), a selective antagonist of the ghre-
lin receptor GH GHS receptor type 1a (GHSR-1a) [28, 29]. To investigate
the role of endocardial endothelium (EE) in the action of obestatin, addi-
tional experiments (n = 5) were performed in papillary muscles treated
with 0.5% Triton X-100 for 1-2 sec. to remove EE, followed by
20–30 min. washout with Tyrode solution [30]. All drug-containing solu-
tions were prepared fresh before the experiments. The basic advantage of
the papillary muscle is to avoid influences of flow and/or beating rate varia-
tion on determining inotropic response (Gregg or garden hose effect) [31].
Isolated perfused heart
The methods were similar to those previously described [32–35]. In
brief, animals were anaesthetized and treated for 10 min. with heparin.
After killing, the chest was opened and the heart rapidly excised. Iso-
lated rat hearts were weighed, attached to the perfusion apparatus and
retrogradely perfused with oxygenated Krebs-Henseleit (KH) buffer
(127 mM NaCl, 17.7 mM NaHCO3, 5.1 mM KCl, 1.5 mM CaCl2,
1.26 mM MgCl2, 11 mM D-glucose), gassed with 95% O2 and 5% CO2.
A small hole in the left ventricular wall was performed to allow drainage
of the Thebesian flow, and a polyvinyl-chloride balloon was placed into
the left ventricle. Left ventricular pressure, coronary flow and perfusion
pressure were continuously monitored to assess the conditions of the
preparation. The hearts were electrically paced at 280 bpm and kept in
to a temperature controlled chamber (37°C). Each heart was allowed to
stabilize for 40 min., after stabilization the preparation was switched to
constant pressure or constant flow perfusion, at which time baseline
parameters were recorded [33, 34, 36].
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Coronary flow studies at constant pressure
perfusion
The effects of obestatin on coronary flow were studied on isolated
hearts perfused at constant pressure (80 mm Hg) both in basal condi-
tions and under stimulation with 1 nM endothelin-1 (ET-1). The basic
advantage of the constant pressure is to avoid influences of pressure
variation on determining vessel tone (myogenic or stress relaxation
responses). The role of NO and PI3K in the vasodilator effect of obesta-
tin was tested using the specific inhibitors L-NNA (1 mM) and Wort-
mannin (WN, 100 nM), respectively (in each case, n = 5) [37].
Ischaemia and reperfusion experiments at
constant flow (CF) perfusion
The cardioprotective effects of obestatin were investigated on isolated
hearts perfused at constant flow. The basic advantage of the constant
flow perfusion is to avoid influences of flow variation in determining
reperfusion injury. CF was adjusted with a proper pump to obtain a typi-
cal coronary perfusion pressure of 80–85 mm Hg during the initial part
of stabilization. Thereafter, the same flow level (9  1 ml/min./g) was
maintained throughout the experiment.
I/R experimental protocols
After the stabilization period, hearts were subjected to a specific proto-
col, which included in all groups a 30 min. of global no-flow ischaemia.
In all groups, the 30 min. of ischaemia were followed by a period of
120 min. of reperfusion (see below). Pacing was discontinued on initia-
tion of ischaemia and restarted after the third minute of reperfusion
[33, 34]. Experimental protocols for groups 1–7 are described in Fig-
ure 1. After stabilization, the hearts of the control group (I/R, Group 1,
n = 6) were exposed I/R protocol only. In Group 2 (OBE-Post group;
n = 9), immediately after ischaemia the hearts were reperfused in the
presence of obestatin (75 nM) for 20 min. Group 3–7 hearts were trea-
ted with obestatin and different specific inhibitors of NO/ROS/PKCe/
mitoK(ATP) channel/GC pathway (Che 1 lM; L-NIO 1 lM; NAC 10 lM;
5-HD 10 lM; ODQ 10 lM; n = 5 for each group). The antagonists were
administered during the last 5 min. of stabilization and the first 20 min.
of reperfusion at the concentrations described previously [33, 34, 38].
These concentrations of the inhibitors did not affect basal cardiac per-
formance, as demonstrated by our preliminary results.
Assessment of myocardial injury
Infarct size was assessed as previously described [32–34]. In brief, the
hearts were removed from perfusion apparatus at the end of reperfu-
sion, and the left ventricles (LV) dissected into 2–3 mm circumferential
slices. Following 20 min. of incubation at 37°C in 0.1% nitro-blue tetra-
zolium in phosphate buffer solution, unstained necrotic tissue was care-
fully separated from stained viable tissue by an independent observer.
The necrotic mass was weighted and expressed as % of total left ven-
tricular mass. Although in this model the whole heart underwent nor-
mothermic ischaemia, only the LV had a fixed volume and preload;
therefore, only the LV mass was considered as risk area.
Western blotting
Immunoblot analysis was performed as previously described [32, 34].
An additional group of hearts perfused with buffer alone for 90 min.
(Sham) was added (n = 3). LV samples were collected after 90 minutes
Group 1: Ischaemia/Reperfusion(I/R)
Stabilization Ischaemia Reperfusion
n.im 021n.im 0340 min.
Group 2: Obestatin-Post (OBE-Post)
Stabilization Ischemia OBE Reperfusion 
30 min.
120 min(R) 
n.im 02n.im 04
Groups3-7: OBE-Post + inhibitors (Che, L-NIO, NAC, 5-HD or ODQ)
Stabilization Ischaemia OBE+In.  noisufrepeR.nI
40 min.
5 min. 30 min. 20 min.
120 min. (R) 
Fig. 1 Experimental protocols. Before ischaemia, hearts were randomly allocated to one of the experimental groups. All the hearts underwent
40 min. of stabilization, 30 min. of ischaemia and 120 min. of reperfusion, for a total of 190 min. Group 1 hearts (I/R, Group 1, n = 6) were
exposed to I/R protocol only. Group 2 hearts were treated with obestatin (75 nM) during the initial 20 min. of reperfusion (OBE-Post group; n = 9).
Group 3–7 hearts were treated with obestatin and different specific inhibitors of NO/ROS/PKCe/mitoK(ATP) channel/GC pathway (Che 1 lM; L-NIO
1 lM; NAC 10 lM; 5-HD 10 lM; ODQ 10 lM; n = 5 for each group). The inhibitors (In.) were administered during the last 5 min. of stabilization
and the initial 20 min. of reperfusion.
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in Sham group, and either after 20 min. of reperfusion in I/R hearts or
at the end of treatment during reperfusion (after 20 min.) for OBE-Post.
All tissues were snap frozen in liquid nitrogen before being stored at
80 °C until protein extraction. Briefly, 50 lg of total proteins for
P-eNOS and PKG-1a were resolved in 8% and 10%, respectively, in
SDS-PAGE and incubated with the specific antibody. Blots were
reprobed with antibodies against total eNOS and actin for PKG-1a, for
normalization.
Statistical analysis
All data are expressed as means  S.E.M. One-Way ANOVA and Tukey’s
HSD (honestly significant difference) for post-ANOVA comparisons were
used to evaluate the statistical significance of the differences between
groups. Significance was established when P < 0.05.
Results
Obestatin blunts b-adrenergic response via an
endothelial-dependent PI3K-Akt-NO-cGMP
pathway in isolated papillary muscle
Under basal conditions, obestatin induced a biphasic effect on
myocardial contractility, characterized by a slight, transient enhance-
ment (at 50 nM: 115.0  3.5% of baseline value, n = 5), followed by
a dose-dependent reduction of developed tension (94.9  5.4,
83.8  4.4 and 62.7  5.3% of baseline value at 25, 50 and
100 nM, respectively). These effects were completely reversible:
20 min. washout restored contractile force to 101.8  1.2% of base-
line values in papillary muscle treated with 100 nM obestatin. More-
over, obestatin (50 nM) exerted a significant antiadrenergic effect,
reducing by 40% the positive inotropic effect of ISO (P < 0.01 versus
ISO alone) (Fig. 2). To test the role of the PI3K/Akt/NO/cGMP path-
way in the antiadrenergic effect of obestatin, papillary muscles were
pre-treated with WN, L-NNA or ODQ before the administration of ISO
or ISO + OBE, to block PI3K, NO or guanylate cyclase activity,
respectively. As shown in Figure 2, all these drugs abolished the anti-
adrenergic effect of obestatin, suggesting that the PI3K/Akt/NO/cGMP
pathway plays an important role in the inotropic effects of this pep-
tide. The positive inotropic effect of ISO alone (196.2  16.8%) was
not modified by the inhibitors (170.2  8.7%, WN + ISO;
178.0  13.9%, L-NNA + ISO; 199.9  24.4%, ODQ + ISO).
The presence of (D-Lys3)-GHRP-6, a selective antagonist of
ghrelin receptor GHSR-1a, did not alter the antiadrenergic effect
of obestatin, suggesting that the action of obestatin does not
involve the ghrelin receptor (P < 0.01 versus ISO). Finally, to ver-
ify if NO may derive from endocardial endothelial cells, we tested
whether the removal of EE would modify the antiadrenergic effect
of obestatin. While removal of EE with 0.5% Triton X-100 did not
significantly modify the inotropic effect of ISO under basal condi-
tions (203.6  16.1% of baseline, n = 5), the antiadrenergic effect
of obestatin was completely blocked (191.8  12.7%,
ISO + OBE).
Obestatin blunts endothelinergic response and
modulates vascular function via PI3K/NO
pathway in isolated rat heart perfused at
constant pressure
In basal conditions, 50 nM obestatin exerted a moderate, but signifi-
cant (P < 0.05 versus control) vasodilator effect (flow =
113.3  2.8% of baseline), which was completely blocked by both L-
NNA and WN (flow = 93.2  2.7 and 96.6  3.5%, respectively;
n = 5 for each group; in both cases, P < 0.05). Importantly, the
vasoconstrictor effect of 1 nM ET-1 (flow = 58.2  3.5% of
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Fig. 2 Antiadrenergic effect of obestatin in isolated rat papillary muscle. The positive inotropic effect of ISO (100 nM) is compared with that exerted
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baseline) was dose dependently reduced by 50 or 75 nM obestatin
(flow = 71.4  4.0 and 83.2  4.9% of baseline, respectively; n = 5
for each group; in both cases, (P < 0.01) (Fig. 3).
Post-ischaemic obestatin blunts I/R injury via
NO-PKG/PKC pathway and mitoK(ATP)-ROS
signalling in isolated rat heart perfused at
constant flow
The administration of obestatin (75 nM) during the early reperfusion
significantly reduced cell damage observed after I/R in the isolated rat
hearts. In particular, infarct size was reduced from 60  8% (I/R
group) to 33  5% (OBE-Post group; P < 0.01 versus I/R group) of
LV mass (Fig. 4). The cardioprotective effect of obestatin was abro-
gated by treatment with the PKC antagonist chelerythrine (Che), the
NOS inhibitor (L-NIO), the ROS scavenger N-acetyl-L-cysteine (NAC),
the mitoK(ATP) channel blocker 5-hydroxydecanoate (5-HD) and the
GC inhibitor (ODQ). The infarct sizes measured in these hearts were
66  9%, 65  11%, 57  2%, 73  3% and 59  8%, respec-
tively (P < 0.01 versus OBE-Post).
Obestatin counteracts the inhibitory effect of I/R
on phosphorylation of eNOS and expression of
PKG-1a
We next investigated the effect of obestatin on activation of eNOS/
NO/PKG pathway, known to be involved in postconditioning [39]. Our
results show that in isolated rat hearts, I/R reduced both the phos-
phorylation of eNOS and the expression of PKG-1a, with respect to
Sham. However, obestatin, given at the time of early reperfusion,
counteracted this effect and strongly increased both phospho-eNOS
(Fig. 5A) and PKG-1a (Fig. 5B). These results further suggest the
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involvement of eNOS/NO/PKG signalling in the cardioprotective action
of obestatin.
Discussion
In the present study, we sought to unveil the role of obestatin as a
regulator of cardiac function, in particular, in stress conditions. Our
results show that obestatin displays an inhibitory tone on the perfor-
mance of rat papillary muscle, both under basal conditions and b-
adrenergic stimulation, through an endothelial-dependent NO/sGC/
PKG pathway. This ‘antiadrenergic’ action suggests a putative coun-
ter-regulatory role for obestatin in cardiovascular homeostasis, by
protecting the heart against b-adrenergic receptor-induced over-
stimulation in conditions of stress. Furthermore, our findings sug-
gest that the same pathway is also implicated in the ability of
obestatin to modulate vascular function and to counteract the effect
of endothelin-1 on vasoconstriction. Obestatin also exerts a post-
conditioning-like effect, by reducing the infarct size in isolated heart
subjected to I/R, through activation of an NO/ROS/PKC pathway,
converging on mitoK(ATP) channel. The involvement of this pathway
is corroborated by evidence showing that obestatin promotes the
phosphorylation of eNOS and expression of PKG-1a, both reduced
by I/R.
Obestatin is a recently discovered amidated peptide, originating
from the ghrelin precursor pre-pro-ghrelin [18, 40]. It has been sug-
gested that both obestatin and ghrelin participate in a complex regula-
tory system; however, the intracellular pathways activated by
obestatin and its role in physiopathological conditions are largely
unknown [18, 41]. Although it has been initially suggested that
obestatin antagonizes the central activities of ghrelin, through inter-
action with the orphan receptor GPR39 [40], studies from our
group and others have shown that obestatin exerts peripheral
actions, including those at the cardiovascular level, similar to those
of acylated and unacylated ghrelin and other GHS [18]. In fact,
ghrelin improves cardiac function [42], displays cardioprotective
effects after I/R injury [17, 43], and inhibits apoptosis in cardiomy-
ocytes and endothelial cells through mechanisms independent of
GHS-R1a, mediated by activation of PI3K/Akt and ERK1/2 [44].
Likewise, obestatin displays a preconditioning-like function against
cardiac alterations induced by I/R [15] or diabetes [45]. Moreover,
like ghrelin, obestatin reduces apoptosis in rat H9c2 cardiac cells
and isolated ventricular myocytes subjected to I/R, through PKC,
PI3K/Akt or ERK1/2 pathways [15]. Recently, obestatin has been
shown to also attenuate doxorubicin-induced cardiac dysfunction
through inhibition of cardiomyocyte apoptosis via nuclear factor
erythroid 2-related factor 2 (Mhrt-Nrf2)-dependent pathway [46]. In
addition, both ghrelin and obestatin levels were found increased in
chronic heart failure (CHF) patients with cachexia; however, the
ghrelin to obestatin ratios were lower in these patients than in con-
trols, suggesting that ghrelin and ratio of ghrelin to obestatin are
independent predictors of the development of cardiac cachexia
[22]. Ghrelin and obestatin levels, as well as the ratio of ghrelin to
obestatin were also higher in spontaneously hypertensive rats, sug-
gesting a role for the ghrelin/obestatin system in the regulation of
blood pressure [23].
The receptor(s) involved in the effects of obestatin has yet to be
determined. In fact, the role of GPR39, the putative receptor for
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obestatin [40], has been questioned by different groups [18, 47, 48],
although binding sites for obestatin have been shown in different cell
types [15, 29, 49, 50]. Our present findings have demonstrated that
the selective antagonist of ghrelin receptor (D-Lys3)-GHRP-6 did not
alter the antiadrenergic action of obestatin, suggesting GHS-R1a-
independent effect of the peptide and involvement of a different
receptor. Interestingly, we have previously shown that the glucagon-
like peptide 1 receptor (GLP-1R) may be implicated in the phys-
iopathological actions of obestatin in several cell types [29, 49, 51,
52]. This may also be possible for cardiomyocytes and endothelial
cells, which express GLP-1R [53], although more studies are needed
to clarify this hypothesis.
Obestatin is likely to play a significant role in cardiovascular func-
tion also in humans, both under physiological and pathological condi-
tions [18, 25]. However, the dose of obestatin used in this study was
several times (about 250-fold) higher than the levels detected in bio-
logical fluids in patients with ischaemic heart disease [19]. Of note, it
must be taken into account that our experimental conditions are quite
different from those present in patients. We studied the effect of a
single acute treatment in a cardiac preparation from a healthy animal,
while in patients we can suppose that the heart is exposed to chroni-
cally elevated levels of obestatin in a pathological scenario, in which a
severe endothelial dysfunction and other circulating mediators are
present.
The ability of obestatin to modulate cardiac contractility in basal
conditions and during b-adrenergic stimulation, confirms and
extends our previous observations on the effects of the synthetic
peptidyl GHS hexarelin and ghrelin with its endogenous derivatives,
on mechanical tension developed by rat and guinea pig papillary
muscles [5, 54]. The cardioprotective action of obestatin, when
infused at the early reperfusion, expands our previous observations
on the positive effects of the peptide when given before an ischae-
mic event [15]. As treatments at the onset of myocardial reperfu-
sion are more feasible than pre-treatments [55–57], the present
results may have a greater relevance, in view of its possible clinical
application.
Regarding the mechanisms of action of obestatin in reducing
infarct size, we show here that the obestatin-induced protection is
abolished by either upstream antagonists, namely the broad range
inhibitor of PKCs, CHE, the NOS blocker L-NIO, as well as by the
downstream target antagonists, such as the mitoK(ATP) channel
blocker, 5HD or the ROS scavenger, NAC. The involvement of the
NO/PKG pathway is confirmed by the co-infusion of obestatin with
specific inhibitor for NO/PKG pathway, and is supported by results
on phosphorylation of eNOS and expression of PKG-1a. Accord-
ingly, several data demonstrate that a pathway similar to that acti-
vated by obestatin is also induced by Post-C manoeuvres [36, 58,
59]. In fact, it is known that I/R reduces the basal myocardial con-
tent of cGMP and the ability of cardiomyocytes to respond to stimu-
lators of cGMP synthesis, and the Post-C manoeuvres abolish these
deleterious effects [36]. Moreover, previous studies have demon-
strated that preservation of the sGC/PKG pathway during reperfu-
sion, using pharmacological strategies to either increase cGMP
synthesis or reduce its degradation, attenuates death of cardiomy-
ocytes [60].
Here, we also show that obestatin exerts a vasodilator action on
coronary vessels, being able to counteract the potent vasoconstrictor
effect of ET-1. Moreover, the coronary dilatory effects of obestatin are
due to stimulation of NOS and NO release from endothelial cells,
through the PI3K/Akt/eNOS pathway. Our findings are consistent with
previous data showing that obestatin induces vascular relaxation in
rat aorta [13] or inhibits endothelin-1-induced vasoconstriction in
humans [25] through activation of endothelium-dependent NO sig-
nalling, indicating that obestatin may be important in the regulation of
vascular function. Therefore, our results suggest a novel physiologi-
cal function for obestatin as a cardiostatin, possibly able to play a rel-
evant role in the natural defence against exaggerated cardiac
hyperactivity. This is the case of the ‘neuroendocrine storm’, where
activation of the sympathetic nervous system (SNS) during heart fail-
ure leads to imbalance of the SNS and vagal activity and to a further
worsening of cardiac dysfunction [61]. Of note, high endothelin-1
levels have been associated with poor outcome after myocardial
infarction [62], making our observations on the effects of obestatin
particularly interesting, as this peptide may be proposed as multiple
target agent able to counteract maladaptive feed-back/responses in
post-ischaemic condition.
In conclusion, this study shows that obestatin induces cardiopro-
tection against I/R injury and counteracts both exaggerated b-adre-
nergic and endothelin-1 activity. Therefore, our findings suggest that
obestatin may play an important role in modulating cardiovascular
function in conditions of stress. In particular, we show that the post-
conditioning-like, antiadrenergic and anti-endothelinergic effects are
dependent on the PI3K/Akt/NO pathway. The fact that obestatin coun-
teracts exaggerated b-adrenergic activity, a relevant part of the neu-
roendocrine scenario in heart failure [63], and dilates coronary
vessels in vitro (present study), as well as human vessels in vivo
[25], suggests that this peptide may exert multiple positive effects. In
line with these evidences, as b-blockade is largely used as post-
ischaemic treatment, and exaggerated endothelinergic response may
be a possible therapeutic target, the present work suggests that
exogenous obestatin may represent a new tool for pharmacological
postconditioning.
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